Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today […]
RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
— Robust pipeline of drugs against validated oncology targets — — Focus on delivering Actinium-225, a powerful alpha-emitting radioisotope — — Led by repeatedly successful management team — October 14, 2020 08:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline […]
